This company listing is no longer active
Biodexa Pharmaceuticals Valuation
Is 5MP0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5MP0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 5MP0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 5MP0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5MP0?
Other financial metrics that can be useful for relative valuation.
| What is 5MP0's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | UK£3.55m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 5MP0's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.7x | ||
ECX Epigenomics | 3.6x | 36.9% | €1.6m |
CNW co.don | 0.7x | n/a | €6.5m |
PJ2 Liminal BioSciences | 43.7x | -149.8% | €11.8m |
SBH Sangui Biotech International | 18.9x | n/a | €1.3m |
5MP0 Biodexa Pharmaceuticals | 5.5x | n/a | €3.5m |
Price-To-Sales vs Peers: 5MP0 is good value based on its Price-To-Sales Ratio (5.5x) compared to the peer average (16.7x).
Price to Earnings Ratio vs Industry
How does 5MP0's PE Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 5MP0 is good value based on its Price-To-Sales Ratio (5.5x) compared to the European Biotechs industry average (9.8x).
Price to Sales Ratio vs Fair Ratio
What is 5MP0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 5MP0's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.